Could your own tumor cells fight your cancer? early trial begins
NCT ID NCT04967833
First seen Jun 27, 2026 · Last updated Aug 06, 2026 · Updated 2 times
Summary
This early-phase trial tests a personalized therapy for people with advanced solid tumors that have not responded to standard treatments. Doctors take immune cells from a sample of the patient's tumor, grow them into large numbers in a lab, and infuse them back into the patient. The goal is to see if this approach is safe and can shrink tumors. Only 20 participants will be enrolled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Tumor-infiltrating lymphocytes (TILs) – immune cells taken from the patient's tumor, multiplied in a lab, and infused back
- What this could lead to
- If it works, this could point toward a new treatment option for people with advanced solid tumors who have run out of standard therapies.
- What could go wrong
- This is a very early, small trial (20 people) focused on safety. The treatment involves strong chemotherapy beforehand, which can cause serious side effects. Success is not guaranteed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tongren Hospital Shanghai Jiao Tong University School Of Medicine.
RECRUITINGShanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.